University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Tom F. Lue

Tom F. Lue, M.D.

Urologist

Dr. Tom Lue is an internationally recognized expert in the treatment of male sexual dysfunction at UCSF Medical Center. In 1983, he was one of the first urologists in the country to offer penile injection for erectile dysfunction. His research team proved that a new class of compound enhances erection in animals, which provided the scientific basis for three medications — Viagra, Levitra and Cialis, the most popular treatments for erectile dysfunction. Lue and his associates also developed the first animal model to study Peyronie's disease and introduced pentoxifylline for treatment.

Lue is vice chair of urology, medical director of the Knuppe Molecular Urology Laboratory and a professor of urology at UCSF. He graduated with highest honors from the Kaohsiung Medical College in Taiwan, completed urologic training at Downstate Medical Center in Brooklyn, N.Y. and was awarded the Valentine Fellowship from the New York Academy of Medicine to study the neurophysiology of the genitourinary tract at UCSF. He has won numerous awards, including the American Urological Association's Gold Cystoscope award and American Foundation of Urologic Disease's "Most Innovative Research Award." Lue has authored or co-authored more than 380 publications and 12 books on male sexual dysfunction.

Clinics

Urology Practice
400 Parnassus Ave., Sixth Floor, Suite A610
San Francisco, CA 94143
Phone: (415) 353-2200
Fax: (415) 353-2641

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Tom F. Lue

Additional Languages

Chinese

Education

Kaohsiung Medical College 1972

Residencies

SUNY Downstate Medical Center, Urology 1981

Fellowships

UCSF Medical Center, Urology

Selected Research and Publications

  1. Lin CS, Lue TF. Re: characterization of the early proliferative response of the rodent bladder to subtotal cystectomy: a unique model of Mammalian organ regeneration. Eur Urol. 2013 Feb; 63(2):401-2.
  2. Lin CS, Lue TF. Defining vascular stem cells. Stem Cells Dev. 2013 Apr 1; 22(7):1018-26.
  3. Lin CS, Albersen M, Xin Z, Namiki M, Muller D, Lue TF. Phosphodiesterase-5 expression and function in the lower urinary tract: a critical review. Urology. 2013 Mar; 81(3):480-7.
  4. Ning H, Albersen M, Lin G, Lue TF, Lin CS. Effects of EdU labeling on mesenchymal stem cells. Cytotherapy. 2013 Jan; 15(1):57-63.
  5. Lue TF, Goldstein M. Surgeries in andrology: optimization and patients' well being. Asian J Androl. 2013 Jan; 15(1):3-4.
  6. Qiu X, Lin G, Xin Z, Ferretti L, Zhang H, Lue TF, Lin CS. Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model. J Sex Med. 2013 Mar; 10(3):738-46.
  7. Kovac JR, Mak SK, Garcia MM, Lue TF. A pathophysiology-based approach to the management of early priapism. Asian J Androl. 2013 Jan; 15(1):20-6.
  8. Wu A, Lue T. Editorial comment. Urology. 2012 Dec; 80(6):1373-4.
  9. Lin CS, Lue TF. Adipose-derived Stem Cells for the Treatment of Peyronie's Disease? Eur Urol. 2013 Mar; 63(3):561-2.
  10. Lin CS, Ning H, Lin G, Lue TF. Is CD34 truly a negative marker for mesenchymal stromal cells? Cytotherapy. 2012 Nov; 14(10):1159-63.
  11. Ning H, Qiu X, Baine L, Lin G, Lue TF, Lin CS. Effects of high glucose on human cavernous endothelial cells. Urology. 2012 Nov; 80(5):1162.e7-1162.e11.
  12. Khurana A, Nejadnik H, Gawande R, Lin G, Lee S, Messing S, Castaneda R, Derugin N, Pisani L, Lue TF, Daldrup-Link HE. Intravenous ferumoxytol allows noninvasive MR imaging monitoring of macrophage migration into stem cell transplants. Radiology. 2012 Sep; 264(3):803-11.
  13. Lin CS, Lin G, Lue TF. Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants. Stem Cells Dev. 2012 Oct 10; 21(15):2770-8.
  14. Qiu X, Villalta J, Ferretti L, Fandel TM, Albersen M, Lin G, Dai Y, Lue TF, Lin CS. Effects of intravenous injection of adipose-derived stem cells in a rat model of radiation therapy-induced erectile dysfunction. J Sex Med. 2012 Jul; 9(7):1834-41.
  15. Orabi H, Lin G, Ferretti L, Lin CS, Lue TF. Scaffoldless tissue engineering of stem cell derived cavernous tissue for treatment of erectile function. J Sex Med. 2012 Jun; 9(6):1522-34.
  16. Lin G, Ning H, Banie L, Qiu X, Zhang H, Lue TF, Lin CS. Bone marrow cells stained by azide-conjugated Alexa fluors in the absence of an alkyne label. Stem Cells Dev. 2012 Sep 1; 21(13):2552-9.
  17. Qiu X, Fandel TM, Ferretti L, Albersen M, Zhang H, Lin G, Lin CS, Schroeder T, Lue TF. Both immediate and delayed intracavernous injection of autologous adipose-derived stromal vascular fraction enhances recovery of erectile function in a rat model of cavernous nerve injury. Eur Urol. 2012 Oct; 62(4):720-7.
  18. Ning H, Lin G, Lue TF, Lin CS. A coculture system of cavernous endothelial and smooth muscle cells. Int J Impot Res. 2013 Mar; 25(2):63-8.
  19. Lue TF. Legends in urology. Can J Urol. 2012 Feb; 19(1):6070-3.
  20. Lin CS, Lue TF. Stem cell therapy for stress urinary incontinence: a critical review. Stem Cells Dev. 2012 Apr 10; 21(6):834-43.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2013 The Regents of The University of California